Company intelligence / Profile preview

Blue Sky Biotech

Vienna, Austria

Ownership: Private
Development stage: Other

Overview

Phase 1 trial of delNS/E6E7 for HPV-induced cervical lesions demonstrated >80% elimination of precancerous lesions with HPV clearance and excellent safety profile. Phase 1 trial for HPV-positive oropharyngeal cancer (BS03) shows strong CD8+ and CD4+ T-cell infiltration and PD-L1 upregulation, supporting combination strategies with checkpoint inhibitors.

Therapeutic areas: Oncology
Modalities: Viral vector therapyOncolytic virus therapy
Industry: Biotech

Partnerships

University of Veterinary Medicine Vienna (equine sarcoids program)

Beyond the preview

Go deeper on Blue Sky Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blue Sky Biotech.

Explore the full profile